Jill Lacy, MD

Professor of Medicine (Medical Oncology)

Clinical Interests

  • Hodgkin Disease
  • Lymphoma
  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Brain Tumor Center | Gastrointestinal Cancer Program | Sarcoma Oncology Program

Medical Oncology: Subset Medical Oncology Faculty

Yale Medical Group

Board Certifications

  • Medical Oncology AB of Internal Medicine (1991)

Clinical Trials

Conditions Study Title
Pancreas Multicenter Randomized Phase II Study of NPC-1C in Combination with Gemcitabine and nab-Paclitaxel versus Gemcitabine and nab-Paclitaxel alone in Patients with Metastatic or Locally Advanced Pancreatic Cancer Previously Treated with FOLFIRINOX
Brain and Nervous System A Phase II Trial of High-Dose Rituximab Combined with Temozolomide as Treatment for Patients with Primary CNS Lymphoma
Other Digestive Organ A Dose Escalation and Cohort Expansion Study of DKN-01 in Combination with Gemcitabine and Cisplatin in Patients with Advanced Carcinoma Primary to the Intra- or Extra-hepatic Biliary System or Gallbladder
Other Digestive Organ, Stomach A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)
Breast - Female, Breast - Male, Lung, Pancreas A Phase 1, Open-Label, Multicenter, Safety Study of Nivolumab (BMS-936558) in Combination with nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Pancreas A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Maintenance Olaparib Monotherapy in Patients with gBRCA Mutated Metastatic Pancreatic Cancer whose Disease Has Not Progressed on First Line Platinum Based Chemotherapy
Esophagus, Other Digestive Organ A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors
Colon, Rectum A double-blind, randomised, placebo controlled Phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer refractory to standard therapies.
Colon A Pilot study of the Role of Omalizumab (Xolair) in Reducing the Incidence of Oxaliplatin-induced Hypersensitivity Reaction (HSR)
Colon, Rectum S1406: Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
Pancreas nab-paclitaxel (Abraxane) plus Gemcitabine in subjects with locally Advanced pancreatic cancer (LAPC): an International, open-label, multi-center, Phase 2 study (LAPACT)
Unknown Sites Tumor Molecular Profiling
Pancreas A phase 3, multicenter, open-label, randomized study of nab-Paclitaxel plus gemcitabine versus gemcitabine alone as adjuvant therapy in subjects with surgically resected pancreatic adenocarcinoma
Pancreas S1313: A Phase Ib/II Randomized Study of Modified FOLFIRINOX +Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma.
Colon S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Pancreas Phase II Study of Peri-Operative Modified Folfirinox in Localized Pancreatic Cancer
Colon E7208: A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Unknown Sites An Investigation of Tumor-Derived Mutated DNA in the Blood and Urine as a Biomarker for Cancer Treatment Response
Colon C80702: A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer

Edit this profile

Contact Info

Jill Lacy, MD
Patient Care Location
Smilow Cancer Hospital at Yale-New HavenYale-New Haven Hospital
20 York Street, Ste North Pavilion 8

New Haven, CT 06510
Mailing Address
PO Box 208028
New Haven, CT 06520-8028